STOCK TITAN

BIONTECH SEC Filings

BNTX NASDAQ

Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

BioNTech SE filings document the disclosures of a foreign private issuer that reports to the SEC primarily through Form 6-K current reports and annual reports on Form 20-F. The records cover interim condensed consolidated financial statements, operating and financial reviews, corporate updates, and exhibit filings related to press releases and investor presentations.

BioNTech’s filings also describe ADS-related capital actions, including repurchase program disclosures for American Depositary Shares representing ordinary shares. Other recurring subjects include annual general meeting invitations and shareholder voting mechanics, governance matters, clinical and regulatory updates for oncology programs, COVID-19 vaccine activity, collaboration-related pipeline information, and material-event disclosures affecting capital allocation and corporate strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
current report

FAQ

How many BIONTECH (BNTX) SEC filings are available on StockTitan?

StockTitan tracks 81 SEC filings for BIONTECH (BNTX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BIONTECH (BNTX)?

The most recent SEC filing for BIONTECH (BNTX) was filed on August 4, 2025.